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STAPHYLOCOAGULASE AS A HEMOSTATIC AGENTh
Staphylocoagulase, a protein produced by Staphylococcus aureus reactc
with a plasma protein designated the Coagulase Reacting Factor (CRF)
which is either prothrombin or is presumed to represent some active com-
ponent of the prothrombin molecule."' The interaction of these two sub-
stances leads to the conversion of fibrinogen to fibrin, a reaction that pro-
ceeds in it*ro in the absence of calcium and in the presence of antico-
agulants such as heparin and dicoumarol. The administration of large
intravenous doses of coagulase to rabbits may result in in tivo defibrino-
genation, sequestration of fibrin in tissues such as the lungs, and even in
acute death.`8 The question has remained open, however, whether appro-
priate lower doses of coagulase may function as systemic hemostatic agents.
It is well established, as in studies of coagulase antigenicity, that some
levels of coagulase are very well tolerated by experimental animals, without
evidence of any untoward effects. The present observations were therefore
undertaken principally to determine whether systemically administered
coagulase may shorten the whole blood clotting time of the experimental
animal, such as the rat, and whether indeed any significant reduction in
blood loss and in the duration of bleeding may be achieved.
MATERIALS AND METHODS
Staphylocoagulase was prepared by Drummond from S. aureus #104 according to
a previously described method.' This preparation contained 0.31 mg. of protein per mg.
of dry weight. The activity was such that when equal volumes of coagulase and non-
inhibitory human plasma were incubated for 18 hours, 0.0001 mg. of coagulase in 0.5
ml. of peptone-saline produced a firm, invertable clot.
CRF titrations consisted in making a series of doubling dilutions of cell-free plas-
ma, generally in the range of 1:10 to 1:160. To 0.2 ml. of plasma dilution, in M/15
phosphate buffer at pH 6.85, 0.2 ml. of bovine fibrinogen (Armour) at a concentra-
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tion of 250 mg./100 ml., in physiological saline, was added. Finally, 0.2 ml. of coagu-
lase in M/15 phosphate buffer at a pH of 6.85 was introduced into each tube as the
stop watch was started. The first visible floccules or wisp of fibrin was taken as the
clotting time.
Rats were of the Sprague-Dawley strain, as specified.
General procedure of adnministering coagulase and withdrawing blood for whole bloodr
clotting determinations
Under Nembutal® anesthesia, the aorta was cannulated through the common carotid
artery, using polyethylene tubes PE 10 (Clay-Adams).' The coagulase was introduced
directly through the cannula into the aorta, and samples of blood were withdrawn
from the same cannula at the indicated time intervals. The cannulas were thoroughly
washed with saline, and no anticoagulants were introduced. White virgin female rats.
were used, weighing an average of 217 grams., with 22 receiving coagulase and 14,
subjected to identical surgery and cannulation, serving as the controls.
Clotting time determinations
Three to five drops of blood were allowed to flow freely from the cannula on a
clean glass plate, taking care that the drops were of uniform size. The blood was
gently teased with the tips of a pair of fine forceps, and observed for the first indica-
tion of fibrin formation. It was found that 3-5 drops of blood collected simultaneously,
checked within 2-3 seconds of each other by the stop watch. All determinations of
clotting were made on 3-5 drops to establish the validity of each reading.
Collection of plasma for CRF and hematocrit determinations
Blood was withdrawn from the aortic cannula, 0.9 ml. into a syringe containing
0.1 ml. of 3.8 percent sodium citrate for the CRF determinations, and 0.02 ml. for the
hematocrit determinations. The cells were removed by centrifugation.
Experimental procedure for determining the action of coagulase on surgically induced
bleeding
White female rats averaging 230 grams in weight were used. Following the tech-
nique of Popovic and Popovic9 the left jugular vein was exposed under Nembutal&
anesthesia through a small neck incision, and a polyethylene cannula, PE #10 (Clay-
Adams) was inserted. Coagulase (0.05 mg.) in physiological saline was introduced
into the cannula of the experimental animals, while the control animals were similarly-
treated except that saline alone was introduced instead of coagulase. The test and
control animals were placed in identical positions on their right sides, and the heads
were supported in a slightly raised position. The tongues were held in place by thread-
ing the base and taping the thread to the table. Thirty minutes after the inoculatiorn
of the coagulase, approximately 0.5 cm. of the tip of the tongue was excised, and the
blood permitted to flow freely into a graduated centrifuge tube for direct measurement
of the blood volume and of the duration of bleeding from the cannula. Eighteen minutes
following the excision of the tip of the tongue, a small cut was made on the toe of the
left hind foot, and the blood loss was similarly measured.
Miscellaneous observations
The rats were observed for overt evidence of distress, such as changes in behavior
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or muscle tone. The heart rate, respiratory rate, and systolic blood pressure, deter-
mined by a Beckman Dynograph, Type RS, were also monitored.
RESULTS
The effect of coagulase on the whole blood coagulation time at intervals up
to 24 hours
In order to determine the extent and duration of coagulase action on
the whole blood clotting time, frequent measurements were made over a
span of 24 hours. These results were obtained with several different doses
of coagulase, and the average values based on 22 test animals and on 14
controls are summarized in Figure 1. Following a single dose of coagulase,
a fall in the clotting time is evident within 10 minutes, persists for some
four hours, and returns to the base line thereafter. Since the control ani-
mals were similarly handled in every respect, the differences noted must be
ascribed to the coagulase preparation rather than to the operative manipula-
tions.
Differences in the whole blood clotting times of indiidual rats before and
after coagulase administration
Preliminary titrations indicated considerable individual variation among
rats in their whole blood clotting times. For example it was found that
while most rats responded with a shortening of the blood clotting time
even at the highest dose of coagulase tested, 0.25 mg., one rat exhibited
markedly prolonged clotting time, suggesting that in this animal in vivo
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FIG. 1. The effect of coagulase on the coagulation time at intervals up to 24 hours.
Each point represents the average of 22 coagulase-treated animals and 14 control ani-
mals respectively.
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defibrinogenation had occurred. Accordingly, lower doses were selected,
such as 0.05 mg. and 0.12 mg. for most of the tests summarized in Table 1.
The clotting time recorded in 22 coagulase-treated rats and in 14 controls
represents the shortest clotting times selected from serial observations made
over a period of four hours. It was found that the mean of the reduction in
the clotting time was 3.02 minutes for the coagulase-treated group, and
1.24 minutes for the control series. The Analysis of Variance Test gave an
F value of 6.084, indicating a probability of less than 0.5 percent that this
difference may be ascribed to chance.
TABLE 1. THE EFFECT OF COAGULASE ON THE CLOTTING TIME OF
INDIVIDUAL RATS
Experimental animal Control animal
Coagulation time
Coagulation time in minutes in minutes
Dosage of Shortest C. T.
No. of coagulase Before After Initial during
rat in mg. coagulase coagulase C. T. experiment
1 0.05 6.50 5.50 6.16 5.60
2 0.05 6.83 4.50 6.16 6.00
3 0.05 5.83 5.00 6.16 5.50
4 0.05 6.50 5.50 6.25 5.50
5 0.05 5.62 4.00 6.25 5.50
6 0.05 6.00 4.50 5.66 5.10
7 0.05 10.90 5.50 10.00 6.00
8 0.05 6.16 5.00 7.25 7.00
9 0.05 9.66 6.00 12.50 9.00
10 0.05 8.50 5.30 5.25 4.50
11 0.05 6.50 3.00 8.33 7.00
12 0.05 6.16 3.50 5.41 4.50
13 0.12 13.50 4.00 5.66 5.00
14 0.12 6.50 5.50 5.12 2.50
15 0.12 7.33 5.50
16 0.12 11.37 4.00
17 0.12 5.66 5.00
18 0.25 9.33 0.50
19 0.25 7.00 3.50
20 0.25 5.25 3.50
21 0.25 5.83 3.50
22 0.25 7.33 5.50
Average values 7.46 4.44 6.86 5.62
Difference between
average values 3.02 minutes 1.24 minutes
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TABLE 2. PLASMA CRF LEVELS OF NORMAL RATS AND 30 MINUTES
AFTER'COAGULASE (Clotting times in seconds)
Plasma Uninoculated 0.2 mg. 0.04 mg.
dilution rats* coag,/kg.** coag,/kg.t
1:10 134 133 124
1:20 147 151 137
1:40 170 176 168
1:80 231 264 247
1:160 378 448 399
Average of 14 rats.
** Average of 10 rats.
t Average of 3 rats.
CRF levels of rat plasma after the administration of coagulase
Since the fall in the clotting times after coagulase inoculation indicates
in vivo activity, it became pertinent to determine whether the level of CRF
of the plasma was affected. The CRF levels of 14 normal rats were first
determined, and when compared to a noninhibitory human plasma, it was
found that normal rat plasmas contain approximately 25-50 percent of
CRF activity present in the human. The CRF content was then determined
in ten rats receiving 0.2 mg. of coagulase per kg. and in three animals given
0.04 mg. per kg. The results are summarized in Table 2. The values repre-
sent CRF levels 30 minutes after the inoculation of coagulase when a maxi-
mal drop in clotting time occurs. It is evident that the plasma level of CRF
is essentially unaffected by the coagulase injection.
The effect of coagulase on surgically induced bleeding in the rat
In this study, the excision of the tip of the tongue proved far more satis-
factory technically than the wound inflicted on the foot pad. While the
volume and duration of blood loss was easily measurable from the tongue,
the blood flow from the foot lesion was often so small that accurate measure-
ment was not possible. The results are summarized in Table 3. It was de-
termined that the amount and the duration of bleeding from the tongue was
reduced in the test animals by approximately 50 percent. The reduction
in blood loss from the toe lesion was similar, but it was not feasible to
measure the duration accurately. The Analysis of Variance Test gave an F
value of 8.79 for the amount of blood loss from the tongue, indicating a
probability of less than 1 percent that the difference of blood loss in the
treated and control groups was due to chance. A similar analysis of the
differences in the duration of bleeding from the tongue gave an F value of
15.442, indicating a probability of less than 0.5 percent that the results
obtained were due to chance.
15YALE JOURNAL OF BIOLOGY AND MEDICINE
TABLE 3. THE EFFECT OF COAGULASE ON SURGICAL BLEEDING IN THE RAT
Bleeding with coagulase treatment Bleeding in control animals
Bleeding Tongue Bleeding Bleeding Tongue Bleeding
from bleeding from from bleeding from
Rat tongue time toe tongue time toe
no. (ml.) (min.) (ml.) (ml.) (min.) (ml.)
1 0.20 - 0.00* 2.00 0.70
2 0.30 0.00 0.70 0.00
3 0.80 4 0.25 3.40 16 0.75
4 0.30 2 0.05 2.70 12 0.10
5 0.85 5 0.00 3.20 15 0.00
6 2.40 6 0.00 2.00 12 1.15
7 2.10 5 0.00 1.90 6 0.00
8 3.50 9 0.00 0.85 4 0.25
9 0.60 4 0.00 3.60 10 0.00
10 1.50 4 0.00 1.40 14 0.50
11 1.40 7 0.50 3.20 15 0.40
12 1.05 3 0.00 3.30 5 0.00
13 1.70 5 0.30 2.50 7 0.60
14 2.00 4 0.00 2.40 6 0.00
15 0.30 3 0.00 1.30 6 0.00
Avg. 1.26ml. 4.69mim. 0.07 ml. 2.29 ml. 9.84min. 0.3ml.
*Volume too small to measure.
Miscellaneous observations
All test and control animals survived, and there was no evidence of dis-
tress or constitutional disturbance. No significant changes were noted in
hematocrit values, heart rate, respiratory rate, or the weight of the animals.
DISCUSSION
The present findings indicate that appropriate doses of coagulase lower
the glass clotting time of rats and reduce the volume of blood loss and the
duration of bleeding following surgical trauma. The tongue lesions proved
to be most satisfactory for monitoring the blood loss. The Analysis of
Variance Test indicates that the results are statistically significant.
Many systemically introduced substances are known to induce transient
hypercoagulation states."0l None of these has found clinical acceptance for
the amelioration of bleeding problems, barring those designed to correct a
specific clotting deficiency, as in the case of antihemophilic globulin. Of
unique interest is ellagic acid`" which, like coagulase, reduces traumatic
bleeding in the rat,'2 and which lowers the silicone and glass clotting times.'l
The duration of activity in the rat is brief, about 20 minutes, and no un-
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toward effects have been observed. All available evidence implicates the
activation of Factor XII as the basis of ellagic acid action.
In contrast to ellagic acid, coagulase does not require the participation of
the chain of clotting factors initiated by the activation of Factor XII.
Coagulase reacts directly with prothrombin and/or Coagulase Reacting
Factor (CRF) of appropriate animal species to form "coagulase-thrombin,"
which then induces the conversion of fibrinogen to fibrin. The reported re-
duction in traumatic bleeding by ellagic acid in the rat' is more striking
than achieved by coagulase. However, it should be noted that the bleeding
was monitored immediately following ellagic acid inoculation, while 30 and
48 minutes elapsed after coagulase administration before the tongue and
foot pad trauma respectively was inflicted. The reduction of glass clotting
time following ellagic acid"8 lasted approximately 10 minutes in the rat, and
up to 60 minutes in other species, while with coagulase the significant re-
duction in glass clotting time persisted over four hours. Thus, in addition
to the difference in the presumed mode of action of the two agents, the
available evidence suggests that the coagulase effect is more sustained and
prolonged than the one induced by ellagic acid.
It may be of interest to speculate on the possible utility and limitations
of coagulase as a systemic hemostatic agent. It is noteworthy that the in
vivo introduction of coagulase leaves the established blood clotting factors
singularly undisturbed, excepting, with appropriate doses, fibrinogen. Ex-
tensive studies in Poland7 and in France8 failed to show any significant
impact on platelets, Factors II, V, VIII, IX, X, XI, XII. No consumption
of CRF was observed, as confirmed by the present study. Coagulase action
requires prothrombin and/or CRF, and fibrinogen. It seems theoretically
possible that coagulase may favor a hypercoagulable state in situations of
simple blood loss, as in trauma, surgery, peptic ulcers, etc. Since coagulase
acts in the presence of such anticoagulants as heparin and dicoumarol, it
is conceivable that it may counteract excessive bleeding induced by such
anticoagulants. There is no obvious reason why coagulase may not be effec-
tive in counteracting bleeding resulting from some specific clotting factor
deficiency, such as antihemophilic globulin, as long as prothrombin and/or
CRF is available and fibrinogen to fibrin conversion can proceed.
In vivo, defibrinogenation`8 by appropriate doses of coagulase imposes
an obvious limitation on its use as a systemic hemostatic agent. However,
the catastrophic potential of severe defibrinogenation is dose and rate de-
pendent, and extensive experience'-18 has established that lower levels of
coagulase are well tolerated by the experimental animal, consistent with
present findings. Recent investigations of the purified enzyme "Arvin,"
derived from the venom of the Malayan Pit-Viper, Ancistrodon rhodostoma
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have provided new insight into the phenomenon of defibrinogenation-' In-
deed, they indicate a considerable margin of tolerance by the host for sig-
nificant defibrinogenation, as in the use of "Arvin" for the therapy of
thrombosis. Thus, the defibrinogenating potential of coagulase does not
per se preclude its trial as a hemostatic agent, provided the safeguards of
proper dose, proper rate of administration, and of monitoring the plasma
fibrinogen level are carried out.
At present, coagulase is not available commercially. Many techniques of
purification have been described,8'"' and there are no insuperable obstacles
to large scale production. Coagulase is an antigen,`8 and conceivably anti-
coagulase may interfere with its action. However, it may be considered a
relatively "poor" antigen, since experimentally adjuvants and hyperim-
munization are generally required to elicit significant neutralizing anti-
bodies. It seems probable that it would be feasible to overcome the effect
of inhibitory antibodies by appropriate coagulase dosages.
Since coagulase is a protein derived from the ubiquitous staphylococcus,
allergic sensitization must be considered as a potential limitation to its use.
Preliminary studies in Yugoslaviae have given an indication of the extent
of this problem. Partially purified coagulase was administered 39 times to
27 patients, at doses ranging from 0.013 mg. to 3.9 mg. per patient, by the
subcutaneous, intramuscular, and intravenous routes. No reactions were
encountered with 23 intravenous inoculations, with one exception. One
individual, receiving the maximal dose of 3.9 mg. developed a light but
reversible shock. No reactions occurred with six intramuscular injections.
Phenomena of hypersensitivity, however, were noted following subcutaneous
inoculation. While no local reactions occurred in ten patients receiving
0.013 mg., one of eleven subjects receiving 0.13 mg., and all four patients
receiving 1.3 mg. of coagulase developed local induration. The local lesions
were as large as 3 X 4 cm., and even greater, reached a maximum in 7-8
hours, and subsided in 24 hours. Occasionally, an elevation of temperature
of I' C. was noted, also subsiding within 24 hours.
At the present time, it is not possible to ascribe the reactions to coagulase
or to co-precipitated impurities in the preparations. No improvement in
bleeding manifestations among the patients was noted, but the dosages
selected were principally designed to explore tolerance rather than to de-
liver effective amounts which might be anticipated to have significant hemo-
static action.
SUMMARY
The intra-aortic administration of purified staphylocoagulase results in
a statistically significant reduction in the whole blood clotting time of rats.
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Following a single well tolerated dose of coagulase, the shortening of the
clotting time persists for at least four hours. The level of coagulase reactinrg
factor (CRF) of the plasma is not reduced at the time of maximal reduc-
tion of the clotting time. The intravenous administration of coagulase re-
sulted in a statistically significant reduction in the amount and duration of
blood loss from tongue lesions of rats. Blood loss was also reduced by 50
percent from lesions of the foot pads of rats.
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